Work

Clinical features of patients with MTAP-deleted bladder cancer.

Year: 2023

Type: article

Abstract: -del (HR = 1.30; 95% CI, 0.64-2.63; P = 0.471). There was no difference in the time from metastatic diagnosis to death (P = 0.6346). Median OS from diagnosis of localized or de novo metastatic disease was 16 months (range 1.5-60, IQR 8-26) for patients with MTAP-del and 24.5 months (range 3-156, IQR 16-48) for patients with MTAP-WT (P = 0.0218), suggesting that time to progression to metastatic disease is shorter in MTAP-del patients. Covariates did not impact significantly overall survival on propensity score matching. In conclusion, MTAP -del occurs in approximately 30% of patients with advanced urothelial carcinoma and defines a subgroup of patients with aggressive features, such as squamous differentiation, frequent bone metastases, poor response to chemotherapy, and shorter time to progression to metastatic disease.

Source: PubMed Central

Authors: Andre L De Souza, Anthony E Mega, John Douglass, Adam J Olszewski, Ece D Gamsiz Uzun, Alper Uzun, Charissa Chou, Fenghai Duan, Jinyu Wang, Amin Ali, Dragan J Golijanin, Sheldon L Holder, Galina G Lagos, Howard Safran, Wafik S El-Deiry, Benedito A Carneiro

Institutions: Brown University, Lifespan, Rhode Island Hospital, Miriam Hospital

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4320507349

FWCI: 2.854

Cites: 34

Cited by: 13

Related to: 10